United Bankshares Declares Third Quarter Dividend
United Bankshares Declares Third Quarter Dividend
United Bankshares, Inc. (“United”) (NASDAQ: UBSI), today announced that its Board of Directors declared a third quarter dividend of $0.37 per share for shareholders of record as of September 13, 2024.
The dividend payout of approximately $50.0 million on 135.2 million shares is payable October 1, 2024. The year of 2023 represented the 50th consecutive year of dividend increases for United shareholders. Only one other major banking company in the USA has achieved such a dividend record.
As of June 30, 2024, United had consolidated assets of approximately $30 billion and is the 38th largest banking company in the U.S. based on market capitalization. United is the parent company of United Bank, which comprises more than 225 offices located throughout Washington, D.C., Virginia, West Virginia, Maryland, North Carolina, South Carolina, Ohio, Pennsylvania, and Georgia.
United’s stock is traded on the NASDAQ Global Select Market under the quotation symbol "UBSI".
W. Mark Tatterson
Chief Financial Officer
(800) 445-1347
View source version on businesswire.com: https://www.businesswire.com/news/home/20240826575901/en/
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks